Analysis of results heterogeneity of NOACs vs warfarin.
收藏NIAID Data Ecosystem2026-03-08 收录
下载链接：
https://figshare.com/articles/dataset/_Analysis_of_results_heterogeneity_of_NOACs_vs_warfarin_/1051362
下载链接
链接失效反馈官方服务：
资源简介：
Given are the main results (including all dosages or the dose with most pronounced efficacy result)* and grouping by regimen (BID or QD) are displayed. BID, twice-daily dosing; FEM, fixed-effects meta-analysis; NOACs, novel oral anticoagulants; QD, once-daily dosing.
Note. Bold font marks nearly absence of heterogeneity, i.e., generation of a common estimate is justified.
*Dose with most pronounced efficacy result: dabigatran 150 mg BID, apixaban 5/2.5 mg BID, rivaroxaban 20/15 mg QD, and edoxaban 60/30 mg QD.
创建时间：
2014-06-09
